Tarix Pharmaceuticals is a clinical stage biopharmaceutical company developing peptide drugs, TXA127 and PanCyte, to address significant unmet medical needs. These peptides are components of the ACE2/Angiotensin (1-7)/Mas pathway in the renin angiotensin system (RAS). We are investigating the use of the peptides in two principal therapeutic areas:
- Ischemic diseases: ischemic stroke recovery, peripheral vascular disease, type 2 diabetes
- Orphan diseases: muscular dystrophies, Marfan syndrome
TXA127 is a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7). PanCyte is a cyclic analogue of TXA127 with an extended half-life. TXA127 and PanCyte have shown striking effects in models of ischemic stroke and peripheral vascular disease. The peptides have also been effective in models of diabetes. Recently, TXA127 has been shown to be effective in models of both Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophy (LGMD). Tarix intends to initiate clinical trials in these indications during 2014.